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S U M M A R Y
Objectives: To determine the effect of anti-tuberculin antibodies in the T-cell proliferation in response to
tuberculin and Candida antigens in individuals with different levels of tuberculosis (TB) risk.
Methods: Sixteen high-risk TB individuals, 30 with an intermediate TB risk (group A), and 45 with a low
TB risk (group B), as well as 49 control individuals, were studied. Tuberculin skin test (TST) results were
analyzed and serum levels of antibodies (IgG and IgM) against puriﬁed protein derivative (PPD) were
measured by ELISA. Tuberculin and Candida antigens were used to stimulate T-cell proliferation in the
presence of human AB serum or autologous serum.
Results: High levels of anti-tuberculin IgG antibodies were found to be signiﬁcantly associated with the
blocking of T-cell proliferation responses in cultures stimulated with tuberculin but not with Candida
antigens in the presence of autologous serum. This phenomenon was particularly frequent in high-risk
individuals with high levels of anti-tuberculin IgG antibodies in the autologous serum when compared to
the other risk groups, which exhibited lower levels of anti-tuberculin antibodies.
Conclusions: Although cellular immunity plays a central role in the protection against TB, humoral
immunity is critical in the control of Mycobacterium tuberculosis infection in high-risk individuals with
latent TB infection.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Only 5–10% of patients with a latent tuberculosis infection
(LTBI) develop an active TB infection (ATBI).1 Cellular immunity
plays a pivotal role in the control of Mycobacterium tuberculosis
infection. However humoral responses are also important for
protection from M. tuberculosis.1,2 This study group has previously
shown that regardless of tuberculin skin test (TST) results, high
anti-tuberculin antibody titers are correlated with protection
against ATBI, providing a reliable indicator of LTBI.3
T-cell responses to tuberculin and Candida antigens were
analyzed in the present study and it was found that T-cell
proliferation can be modiﬁed by anti-tuberculin-speciﬁc anti-
bodies. This indicates a signiﬁcant role of humoral immunity
against tuberculin in LTBI.
2. Methods
Sixteen high-risk (HR) TB subjects (spouses, physicians, and
signiﬁcant others), 30 nurses with variable degrees of M.
tuberculosis exposure considered at intermediate risk of TB (group
A), and 45 hospital employees (security, administrative personnel)
with a low TB risk (group B) were studied; the mean age of the
subjects was 42  11.4 years. Participants were recruited from the
Tuberculosis Clinic, Hospital Santa Clara, Bogota, Colombia. Forty-
nine healthy controls (mean age 33  13.5 years), with no history of
ATBI exposure, were also included. Subjects were recruited between
2002 and 2006 and we did not include immunocompromised
individuals, patients using steroids, or patients with neoplasias.
The duration of exposure to ATBI patients of the high-risk contacts
studied was >6 months for spouses and signiﬁcant others and >10
years for physicians. The duration of exposure for intermediate and
low-risk individuals was >5 years.
The Institutional Review Board of Hospital Santa Clara and of
the Dana-Farber Cancer Institute approved the study protocol;
subjects provided signed consent. The TST was performed and
serum levels of antibodies (IgG and IgM) against puriﬁed protein
derivative (PPD) were measured as described previously.3Figure 1. T-cell proliferation induced by tuberculin or Candida antigens in the different 
cells for individuals from each of the groups in the presence of human AB or autologous s
with autologous serum (with high levels of anti-tuberculin IgG antibodies, black solid b
tuberculin (Bar graph A), but not with Candida antigen stimulation (Bar graph B). Only
presence of autologous serum.T-cell proliferation assays were performed by duplicate in the
presence of tuberculin or Candida antigens. Brieﬂy, peripheral
blood mononuclear cells (PBMCs; 1  105) from 13 HR, 12 group A,
and 15 group B individuals were incubated with (1) phytohemag-
glutinin (2 mg/ml; Sigma-Aldrich, St. Louis, MO, USA); (2) Candida
albicans (20 mg/ml; Green laboratories, Lenoir, NC, USA), and (3)
tuberculin (10 mg/ml; Mycos Research LLC, Loveland, CO, USA) in
the presence of human AB serum or autologous serum for 3 days at
37 8C in 5% CO2. Cells were labeled with 3H-thymidine (1 mCi/well)
and the radioactivity was measured. Differences were analyzed
with the Student’s t-test and Chi-square or Fisher’s exact method;
p-values of <0.05 were considered signiﬁcant.
3. Results
The baseline characteristics of the individuals studied are
shown in the Supplementary Material (Table S1). The HR group
showed a higher frequency of negative TST (>80%) compared to
group A (60%, p = 0.01) and group B (37%, p = 0.001). High serum
levels of anti-tuberculin IgG antibodies were observed predomi-
nantly in HR individuals (93.7%) when compared to the interme-
diate risk (group A; 43.3%, p = 0.003) and low risk (group B; 26.6%,
p = 0.001) groups (Supplementary Material, Table S2). T-cells
isolated from HR subjects with high levels of anti-tuberculin IgG
antibodies exhibited higher proliferation after stimulation with
tuberculin in the presence of human AB serum when compared to
the other groups (Supplementary Material, Table S3).
Tuberculin and Candida antigens induced high proliferation,
particularly in the HR group (Figure 1, Table 1). All HR subjects (13/
13, 100%) exhibited proliferation with both stimulations, whereas
4/15 (26.6%) individuals in group B showed proliferation (p < 0.05).
To assess the proliferation blocking capacity of anti-tuberculin
antibodies, T-cell proliferation was measured in the presence of
autologous serum or human AB serum. A signiﬁcant blocking of T-
cell proliferation in cultures stimulated with tuberculin in the
presence of autologous serum (presence of anti-tuberculin IgG
antibodies) was found. Eleven of the 13 (84.6%) HR individuals
exhibited this capacity to block T-cell proliferation in the presenceTB risk groups. Bar graph depicting the stimulation index (proliferation) levels of T-
erum: high-risk (HR), intermediate risk (group A), and low risk (group B). Treatment
ars) provokes the blocking of T-cell proliferation responses after stimulation with
 one subject from group B and two from group A exhibited blocking activity in the
Table 1
Proliferation assays after stimulation with tuberculin or Candida antigens in the presence of human AB serum or autologous serum in the different risk of exposure to active
TB infection groups
No. Risk group Cultures with tuberculin Cultures with Candida antigens Anti-tuberculin
antibodies (OD)
SI human AB SI autologous Blocking SI human AB SI autologous Blocking IgM IgG
1 HR 561.50 133.40 (+) 37.40 42.30 () 0.201 0.346
2 HR 200.40 97.10 (+) 120.10 130.80 () 0.228 0.221
3 HR 144.10 36.50 (+) 115.80 128.70 () 0.222 0.250
4 HR 78.80 30.00 (+) 49.90 51.80 () 0.223 0.210
5 HR 78.00 48.00 (+) 55.10 58.90 () 0.301 0.210
6 HR 31.70 15.22 (+) 42.50 40.90 () 0.149 0.348
7 HR 27.70 29.60 () 17.90 20.80 () 0.324 0.869
8 HR 17.00 10.00 (+) 39.80 36.80 () 0.351 0.256
9 HR 7.08 2.90 (+) NP NP - 0.230 0.330
10 HR 72.80 39.20 (+) 49.90 39.00 (+) 0.161 0.734
11 HR 42.10 22.40 (+) 20.40 28.30 () 0.087 0.527
12 HR 301.70 107.90 (+) 89.70 92.00 () 0.115 0.292
13 HR 44.40 78.70 () 16.80 20.10 () 0.176 0.249
1 B 309.60 122.40 (+) 30.10 33.20 () 0.168 0.206
2 B 19.48 23.28 () 41.00 44.00 () 0.140 0.152
3 B NP NP - NP NP - 0.116 0.174
4 B NP NP - 1.80 0.90 () 0.114 0.058
5 B NP NP - NP NP - 0.112 0.213
6 B NP NP - NP NP - 0.208 0.178
7 B NP NP - NP NP - 0.133 0.134
8 B NP NP - 5.20 4.90 () 0.198 0.104
9 B NP NP - NP NP - 0.249 0.079
10 B NP NP - NP NP - 0.066 0.105
11 B NP NP - NP NP - 0.165 0.106
12 B NP NP - NP NP - 0.567 0.066
13 B NP NP - NP NP - 0.105 0.075
14 B 18.00 30.30 () 17.30 29.30 () 0.063 0.451
15 B 279.70 455.90 () 58.80 60.10 () 0.141 0.265
1 A 53.85 29.24 (+) 56.20 50.80 (+) 0.259 0.371
2 A 19.33 14.21 (+) 42.10 44.80 () 0.191 0.312
3 A 15.63 46.1 () 48.0 50.9 () 0.162 0.210
4 A NP NP - NP NP - 0.190 0.110
5 A 43.94 45.91 () 19.30 19.0 () 0.315 0.317
6 A 51.07 20.21 (+) 37.70 39.90 () 0.081 0.219
7 A NP NP - 1.10 1.30 () 0.294 0.256
TB, tuberculosis; SI, stimulation index; OD, optical density; HR, high risk; B, low risk; A, intermediate risk; NP, no proliferation.
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group B had this blocking effect (p < 0.05) (Table 1, Figure 1A).
Only 1/13 (7.6%) HR subjects exhibited blocking after stimulation
with Candida and treatment with autologous serum (Figure 1B).
Considering all individuals in whom blocking of proliferation
was observed regardless of the risk group, 15/22 displayed
blocking of T-cell proliferation in the presence of autologous
serum after stimulation with tuberculin, whereas only 1/21
exhibited blocking in cultures stimulated with Candida antigens
(p = 0.0001).
4. Discussion
One-third of the world’s population is thought to have LTBI, a
condition in which individuals are infected by M. tuberculosis
without active disease, but are at risk of reactivation if their
immune system fails.1,2,4 Immune mechanisms of M. tuberculosis
infection control involve innate and acquired immunity.2,3 As
reported previously, there is crosstalk between different experi-
mental exposure to pathogens including C. albicans and M.
tuberculosis in the speciﬁc and innate immune responses.3 Many
attempts have been made to induce protective T-cell responses to
M. tuberculosis antigens,1 but the failure to produce cellular
protection against M. tuberculosis is possibly due to the high
conservation of M. tuberculosis T-cell epitopes, resulting in an
escape from immunity.5 The present results indicate that cellular
proliferation induced by tuberculin and the levels of anti-
tuberculin antibodies are useful to detect LTBI. Thus, there iscrosstalk between Candida and tuberculin stimulated T-cells
involving effector functions,6 but the blocking activity speciﬁc to
tuberculin is mediated by antibodies.
The protective role of humoral immunity against M. tuberculosis
has been documented previously.7,8 High levels of IgM anti-M.
tuberculosis glycolipid antigens and IgG4 antibodies against DAT
glycolipid antigen of the M. tuberculosis cell wall have been
associated with a high prevalence of TST anergy.9 Recent studies
have demonstrated that humoral responses against mycobacterial
antigens are improved after Mycobacterium bovis PPD administra-
tion.10 Importantly, the estimation of T-cell proliferation to
tuberculin and the levels of IgG anti-tuberculin antibodies may
be a good proxy for the detection of LTBI; however, the design of
this study does not allow a comparison with other diagnostic tests,
such as interferon-gamma release assays (IGRAs).
These results support the importance of the humoral response in
the diagnosis and prevention of M. tuberculosis infection. Anti-
tuberculin antibodies may inﬂuence (1) M. tuberculosis opsonization
and phagocytosis, (2) type II hypersensitivity, and (3) natural killer
(NK) cells killing by antibody-dependent cellular cytotoxicity.
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